Trova i centri medici partecipanti e lo stato attuale dello studio in ciascuno di essi
Trova centri medici partecipanti
Studio per valutare l’efficacia e la sicurezza di ocrelizumab in pazienti con sclerosi multipla recidivante-remittente (SMRR) in stadio iniziale
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
Disordini autoimmuni Sclerosi multipla (SM) Sclerosi multipla recidivante-remittente (RRMS)
Risultati dello studio
LPS MA30143 ENSEMBLE Final Results September 2023 English
(PDF, 0.3 MB)
LPS MA30143 ENSEMBLE Final Results September 2023 Canada French
(PDF, 0.3 MB)
LPS MA30143 ENSEMBLE Final Results September 2023 Netherlands Dutch
(PDF, 0.8 MB)
LPS MA30143 ENSEMBLE Final Results September 2023 Brazil Portuguese
(PDF, 0.4 MB)
LPS MA30143 ENSEMBLE Final Results September 2023 Spain Spanish
(PDF, 0.7 MB)
LPS MA30143 ENSEMBLE Final Results September 2023 Slovakia Slovak
(PDF, 0.7 MB)
LPS MA30143 ENSEMBLE Final Results September 2023 Denmark Danish
(PDF, 1.3 MB)
LPS MA30143 ENSEMBLE Final Results September 2023 France French
(PDF, 0.3 MB)
LPS MA30143 ENSEMBLE Final Results September 2023 LA Spanish
(PDF, 0.2 MB)
LPS MA30143 ENSEMBLE Final Results September 2023 Mexico Spanish
(PDF, 0.3 MB)
LPS MA30143 ENSEMBLE Final Results September 2023 Turkey Turkish
(PDF, 1.6 MB)
LPS MA30143 ENSEMBLE Final Results September 2023 Slovenia Slovenian
(PDF, 0.7 MB)
LPS MA30143 ENSEMBLE Final Results September 2023 Italy Italian
(PDF, 0.6 MB)
LPS MA30143 ENSEMBLE Final Results September 2023 German Germany
(PDF, 0.7 MB)
LPS MA30143 ENSEMBLE Final Results September 2023 Romania Romanian
(PDF, 0.6 MB)
LPS MA30143 ENSEMBLE Final Results November 2023 Portugal Portuguese
(PDF, 0.5 MB)
Esplora studi correlati
Per la versione più aggiornata di queste informazioni per favore vai su www.peripazienti.roche.it
Condividi le informazioni su questo studio
Link to Pageutilizzando una di queste opzioni
Copiato negli appunti!